NEURODEGENERATION

Genetic predisposition and modifiable risks for late-life dementia

Article metrics

Modifiable lifestyle risk factors are able to reduce dementia risk only in people with low genetic risk.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: The interaction between genetics and lifestyle on dementia risk.

References

  1. 1.

    Licher, S. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0547-7 (2019).

  2. 2.

    Lourida, I. et al. J. Am. Med. Assoc. https://doi.org/10.1001/jama.2019.9879 (2019).

  3. 3.

    Lyall, D. M. et al. Neurology 92, e2691–e2698 (2019).

  4. 4.

    Dekhtyar, S. et al. Ann. Neurol. 86, 68–78 (2019).

  5. 5.

    Canevelli, M. et al. Front. Neurol. 8, 628 (2017).

  6. 6.

    Rogers, N. T., Steptoe, A. & Cadar, D. Sci. Rep. 7, 15746 (2017).

  7. 7.

    Wallace, L. M. K. et al. Lancet Neurol. 18, 177–184 (2019).

  8. 8.

    MacLullich, A. M., Beaglehole, A., Hall, R. J. & Meagher, D. J. Int. Rev. Psychiatry 21, 30–42 (2009).

  9. 9.

    Persico, I. et al. J. Am. Geriatr. Soc. 66, 2022–2030 (2018).

  10. 10.

    Adamis, D., Devaney, A., Shanahan, E., McCarthy, G. & Meagher, D. Age Ageing 44, 318–321 (2015).

  11. 11.

    Davis, D. H. et al. JAMA Psychiatry 74, 244–251 (2017).

  12. 12.

    Livingston, G. et al. Lancet 390, 2673–2734 (2017).

Download references

Author information

Correspondence to Kenneth Rockwood.

Ethics declarations

Competing interests

In addition to academic and hospital appointments, K.R. is President and Chief Science Officer of DGI Clinical, which in the past 5 years has contracts with pharma and device manufacturers (Baxter, Baxalta, Biogen, Shire, Hollister, Nutricia, Roche, Otsuka) on individualized outcome measurement. In 2017, he attended an advisory board meeting with Lundbeck. Otherwise, any personal fees are for invited guest lectures, rounds and academic symposia, received directly from event organizers, for presentations on frailty. He is Associate Director of the Canadian Consortium on Neurodegeneration in Aging, which is funded by the Canadian Institutes of Health Research (CAN-137794), with additional funding from the Alzheimer Society of Canada and several other charities, as well as from Pfizer Canada and Sanofi Canada (in Phase 1, 2014–2019). He receives career support from the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research, and research support through grants from the Canadian Institutes of Health Research, the Canadian Frailty Network, the Nova Scotia Health Research Foundation, the Nova Scotia Health Authority Research Fund and the Fountain Family Innovation Fund of the QEII Health Science Centre Foundation.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rockwood, K., Wallace, L.M.K. & Davis, D.H. Genetic predisposition and modifiable risks for late-life dementia. Nat Med 25, 1331–1332 (2019) doi:10.1038/s41591-019-0575-3

Download citation